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Background: Although a previous meta-analysis reported no association between metabolic syndrome (MetS)
and prostate cancer risk, a number of studies suggest that MetS may be associated with the aggressiveness and
progression of prostate cancer. However, these results have been inconsistent. This systematic review and meta-
analysis investigated the nature of this association.
Methods: We systematically searched MEDLINE, EMBASE and bibliographies of retrieved studies up to January 2013
using the keywords “metabolic syndrome” and “prostate cancer”. We assessed relative risks (RRs) of the prostate
cancer, several parameters of prostate cancer aggressiveness and progression associated with MetS using 95%
confidence intervals (95% CIs).
Results: The literature search produced 547 hits from which 19 papers were extracted for the meta-analysis. In
cancer-free population with and without MetS, the combined adjusted RR (95% CI) of prostate cancer risk and
prostate cancer-specific mortality in longitudinal cohort studies is 0.96 (0.85 ~ 1.09) and 1.12 (1.02 ~ 1.23)
respectively. In the prostate cancer patients with and without MetS, the combined unadjusted OR (95% CI) of high
grade Gleason prostate cancer is 1.44 (1.20 ~ 1.72), the OR of advanced prostate cancer is 1.37 (1.12 ~ 1.68) and the
OR of biochemical recurrence is 2.06 (1.43 ~ 2.96).
Conclusions: The overall analyses revealed no association between MetS and prostate cancer risk, although men
with MetS appear more likely to have high-grade prostate cancer and more advanced disease, were at greater risk
of progression after radical prostatectomy and were more likely to suffer prostate cancer-specific death. Further
primary studies with adjustment for appropriate confounders and larger, prospective, multicenter investigations are
required.
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In men, prostate cancer (PCa) is the most frequently
diagnosed malignancy in industrialized countries [1] and
it is the second most commonly diagnosed cancer and
the sixth leading cause of cancer death worldwide [2].
There is a clear need for a better understanding of the
risk factors related to PCa development and progression.
Age, race and family history are the only established
prostate cancer risk factors and these factors are all non-
modifiable. Recently, modifiable lifestyle factors such as
physical activity and diet have been investigated. Because
a higher incidence of PCa was associated with a higher
prevalence of “western” lifestyle, it has been suggested
that these lifestyle factors play a significant role in the
pathogenesis of PCa [3].
Metabolic syndrome (MetS) is a cluster of cardiovas-
cular risk factors that includes hypertension, diabetes
mellitus, obesity, hypertriglyceridemia, and low high-
density lipoprotein cholesterol, with insulin resistance as
the underlying hallmark feature [4]. The prevalence of
MetS has been increasing worldwide and has become a
major public health problem in many western countries.
For example, 35%-41% of adults in the USA are reported
to exhibit MetS [5]. Recently, increasing evidences sug-
gests that MetS may be involved in the development and
progression of certain types of cancer as an independent
etiologic factor including breast cancer [6], endometrial
cancer [7], colorectal cancer [8], pancreatic cancer [9]
and prostate cancer [10]. MetS was firstly observed as a
composite factor associated with prostate cancer risk in
2004 [11], and more studies have since reported the
association between MetS and prostate cancer. However,
the studies investigating the association between MetS
and prostate cancer risk have reported inconsistent fin-
dings [12-21].
It is crucial to review and evaluate the magnitude to
which MetS affects the development and progression of
PCa, as proper management of this modifiable lifestyle
factor may help improve PCa outcomes.
A recently performed meta-analysis study summarized
the association between MetS and the incidence of some
common cancer types, including prostate cancer. The
results, based on 14 databases, revealed that MetS was
not associated with prostate cancer risk [22]. However, a
new investigation on MetS and prostate cancer risk was
published recently [19], and much increasing evidence
in the latest investigations suggests that MetS may be
associated with the aggressiveness and progression of
PCa; prostate cancer patients with MetS may suffer
more aggressive disease and adverse clinical outcomes
[19,23-27]. However, inverse results [28] or no signifi-
cant associations [14,20,29,30] have been reported in
other studies. Therefore, to thoroughly investigate the
nature of this association, we focused on longitudinalcohort studies and conducted a new meta-analysis to
confirm the association between MetS and prostate can-
cer risk by searching the latest literature. Subsequently,
we performed another meta-analysis to quantitatively
summarize several parameters of PCa aggressiveness and
progression, including Gleason score, clinical stage, bio-
chemical recurrence and prostate cancer-specific morta-
lity associated with MetS.
Methods
Search strategy
We systematically searched MEDLINE, EMBASE through
January 2013 for human studies on the association be-
tween MetS and PCa with the following medical subject
heading terms and/or text words: “metabolic syndrome”,
“insulin resistance syndrome”, or “syndrome X”, combined
with “prostate cancer”, “prostatic cancer”, “prostate neo-
plasm”, or “prostatic neoplasm”. We also manually
searched relevant journals, bibliographies, and reviews for
additional articles. The search had no language restriction.
Inclusion criteria
The eligibility of each study was assessed independently
by two investigators (YX and HX). We included only
cohort studies of MetS and prostate cancer risk or pros-
tate cancer-specific mortality and clinical studies of MetS
and Gleason score or clinical stage at diagnosis or bio-
chemical recurrence after treatment. We included studies
that reported standardized forms of relative risk, risk ratio,
hazard ratio or odds ratio with estimates of confidence
intervals (CIs) or with sufficient data to estimate CIs. We
used relative risks (RRs) to represent various effect esti-
mates in a cohort study in this meta-analysis.
Exclusion criteria
We excluded reviews, editorials, meta-analysis and animal
studies. Among the 23 studies that underwent full-text
reviews, we excluded a study on MetS and prostate cancer
risk of re-biopsy [31], a study that did not use a standard
definition of MetS [32,33] and one case-control study on
MetS and prostate cancer risk [21]. For studies previously
published on the same database [34,35], we included only
the most recent findings [19,20]. All of the studies on
which we focused reported RRs with 95% CIs or sufficient
data to estimate them.
Data extraction
The data extracted included publication data (the first
author’s last name, year of publication, and country of the
population studied), study design, population resources,
number of cases, risk estimates with their corresponding
CIs, and variables controlled for by matching or in the
most adjusted model. Abstractions of the data elements
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results were resolved by consensus.
Statistical analysis
Firstly, we updated the data and attempted to analyze the
association of MetS with the prostate cancer risk in longi-
tudinal cohort studies only. Subsequently, we assessed the
association between MetS and prostate cancer-specific
mortaligy in cohort studies and between MetS and high
grade Gleason PCa and/or advanced PCa or biochemical
recurrence in clinical studies. We pooled all of the RRs for
MetS and assessed the heterogeneity between the studies
by Q and I2 statistics, which are distributed as x2 statistics
[36]. A value of P < 0.10 was used to indicate lack of
homogeneity (heterogeneity) among effects. We used a
fixed-effects model if I2 value significance was <0.1; other-
wise, we used a random-effect model. Sensitivity analysis
was conducted by omitting one study at a time, generating
the pooled estimates and comparing with the original esti-
mates. Funnel plots and both Begg’s and Egger’s tests were
used to evaluate publication bias. All analyses were per-
formed using STATA version 9.0 statistical software (Stata,
College Station, Texas, USA). All statistical comparisons




Nineteen studies met the search inclusion and exclusion
criteria. The characteristics of included studies are
presented in Tables 1 and 2.
Detailed search steps are described in Figure 1. Briefly,
from the initial literature search we identified 547
abstracts. Twenty-three articles were considered of inte-
rest and full text of each article was retrieved for detailed
evaluation. Eleven studies investigated the association
between MetS and prostate cancer [11-21]. Nine of them
were longitudinal cohort studies that reported the RRs
of PCa in cancer-free population with and without MetS
[7-15]. Seven studies evaluated MetS and pathological
and clinical stages of PCa, of these studies, 7/7 investi-
gate Gleason score [20,23-26,28,29] and 4/7 investigated
clinical stage [20,23,24,29]. Two case-control studies
explored biochemical recurrence after primary treatment
[23,27], and three longitudinal cohort studies focused on
prostate cancer-specific mortality [14,19,30].
Main findings
Prostate cancer risk
Result from a meta-analysis based on nine longitudinal
cohort studies revealed that there was no association
between MetS and prostate cancer risk (RR = 0.96, 95%
CI 0.85-1.09 n = 9 studies) (Figure 2).Prostate cancer aggressiveness
High grade Gleason score The definition of high grade
Gleason score is ≥ 7 or > 7. A trend for a 36% increased
risk of a high Gleason score in patients with MetS
(OR = 1.36, 95% CI 0.90-2.06 n = 7 studies) was identi-
fied based on a meta-analysis of seven total relative
databases (Figure 3).
Advanced clinical stage Advanced clinical stage was
defined as a clinical stage ≥ T3. Four databases were
included in the analysis of the association of MetS with
advanced clinical stage. The analysis revealed that MetS
was significantly associated with a 37% increased risk of
advanced clinical stage (OR = 1.37, 95% CI: 1.12 ~ 1.68;
n = 4 studies) (Figure 4).
Prostate cancer progression
Biochemical recurrence Only two databases [23,27]
focused on the association of MetS which biochemical
recurrence. The Individual study results and the overall
summary results are presented in Figure 5. The result
indicates that MetS was significantly associated with
2-folds of increased risk of biochemical recurrence
(OR = 2.06, 95% CI: 1.43-2.96, n = 2 studies).
Prostate cancer-specific mortality Three cohort stud-
ies [14,19,30] investigated how MetS affected prostate
cancer-specific mortality. The meta-analysis revealed
that MetS was significantly associated with a higher
risk of the prostate cancer-specific death (RR = 1.12, 95%
CI: 1.02 ~ 1.23; n = 3 studies) (Figure 6).
Sensitivity analysis
We conducted sensitivity analysis by omitting one
study at a time, generating the pooled estimates and
comparing the pooled estimates with the original esti-
mates. Omitting any one of nine studies concerning
MetS and prostate cancer risk or omitting any one of
four studies concerning MetS and advanced clinical
stage produced no dramatic influence on the original
pooled RRs. Omitting Jeon 2012 database [28] in the
7 studies concerning MetS and Gleason score pro-
duced a significant OR = 1.44 (95% CI: 1.20 ~ 1.72),
whereas none of the remaining severn studies exhib-
ited a significant influence on the original estimates.
For biochemical recurrence and prostate cancer-
specific mortality, there were too few studies to do a
sensitivity analysis.
Publication bias
Visual inspection of the Begg funnel plot for both PCR
and Gleason score did not reveal the asymmetry typically
associated with publication bias (Figure 7). Evidence of
Table 1 Characteristics of cohort studies of metabolic syndrome and prostate cancer risk




Cohort size Definition of MetS No. of
cases
RRs 95% CI Controlled
variables
Laukkanen 2004 [11] Finland Kuopio communities 52.6 15 1984-2001 1,880 WHO 56 RR 1.90 1.1-3.5 Age
Tande 2006 [12] United States ARIC* (49% white,
51% African American)
45-64 12.1 1987-2000 6,429 NCEP-ATP-III 385 RR 0.77 0.60-0.98 Age, race
Russo 2008 [13] Italy A pharmacologically
based diagnosis
40 2.7 1999-2005 NA A pharmacologically based diagnosis 94 RR 0.93 0.75-1.14 Age
Martin 2009 [14] Norway HUNT2 48 ± 16.4 9.3 1996-2005 29,364 NCEP-ATP-III 687 RR 0.91 0.77-1.09 Age+
Inoue 2009 [15] Japan Japan PHC population 40-69 10.2 1993-2004 9,548 IDF 119 HR 0.76 0.47-1.22 Age+
Grundmark 2010 [16] Sweden ULSAM 50 30.3 1970-2003 2,183 NCEP-ATP-III 226 RR 1.29 0.89-1.88 Age
2,287 IDF 234 RR 1.18 0.81-1.71
Wallner 2010 [17] United States Olmsted County 40-79 15 1990-NA 2,445 WHO 206 HR 0.65 0.37-1.10 Age
Osaki 2011 [18] Japan The population-based
cancer registry
60.5 ± 10.8 9.3 1992-2007 8,239 NCEP-ATP-III 152 HR 1.37 0.91-2.06 Age
8,239 IDF 152 HR 1.18 0.74-1.90
Häggström 2012 [19] Norway Me-Can 44 12 NA 289,866 Upper quartile levels ATP-III criteria 6,922 RR 0.96 0.92-1.00 Age+
Sweden
Austria
MetS =metabolic syndrome; PCa = prostate cancer; RRs = Relative risks; CI = confidence interval; Age + =At least age; WHO =World Health Organization;
NCEP-ATP-III = National Cholesterol Education Program Adult Treatment Panel III; IDF = International Diabetes Federation; HUNT 2 = Nord-Trondelang


















Table 2 Characteristics of studies of metabolic syndrome and parameters of prostate cancer
Author yr (ref. no.) Country Study design Population Mean age,yr Time period Definition Vof MetS No. of
cases
Outcomes RRs 95% CI




64.8 ± 6.2 2004-2006 NCEP-ATP-III 261 Gleason score ≥7(4 + 3) 0.972 0.637-1.482





GECAP 62.3 1999-2004 NCEP-ATP-III 637 Gleason score ≥7(4 + 3) 1.2 0.64-2.27





Patients with PC who
underwent surgical treatment
64.8 ± 6.97 1990-2007 WHO 210 Gleason score >7 3.346 1.144-9.791





Patients who underwent robot
assisted radical prostatectomy
60.7 ± 6.9 2005-2008 IDF 2756 Gleason score ≥7(4 + 3) 1.328 0.978-1.802






prostate biopsy for PSA
> 4 ng/ml or abnormal DRE
69 2009-2011 NCEP-ATP-III 83 Gleason score ≥7 3.82 1.33-10.9
Clinical stage ≥ T3 NA NA
Jeon 2012 [28] Korea Cross-section
study
Patients who underwent
prostate biopsy for PSA
> 4 ng/ml or abnormal DRE
68.86 ± 8.95 2003-2011 NCEP-ATP-III 90 Gleason score ≥7(4 + 3) 0.101 0.022-0.473
Clinical stage ≥ T3 NA NA
Morote 2012 [26] Spain Cross-section
study
Patients who underwent
prostate biopsy for PSA
> 4 ng/ml or abnormal DRE
68(46-79) 2006-2010 NCEP-ATP-III 848 Gleason score >7 1.75 1.260-2.414





Patients with PC who
underwent surgical treatment
64.8 ± 6.97 1990-2007 WHO 210 Biochemical recurrence 2.73 1.65-4.50




60.9 1999- 2004 NCEP-ATP-III 383 Biochemical recurrence 1.5 0.90-2.6
Jaggers
2009 [30]
United States Cohort study Aerobics Center
Longitudinal Study
20-88 1977-2003 NCEP-ATP-III 185 Mortality 1.32 0.63-2.77





Cohort study Me-Can 44 NA Upper quartile
Levels ATP-III criteria
961 Mortality 1.13 1.03-1.25
PCa = prostate cancer; RRs = Relative risks; CI = confidence interval; WHO =World Health Organization; NCEP-ATP-III = National Cholesterol Education Program Adult Treatment Panel III; IDF = International Diabetes


















19 Included in meta-analysis 
9  Cohort studies on MetS and  prostate  cancer risk in prostate  cancer-
free population
7  Studies on MetS and high grade Gleason prostate cancer
4  Studies on MetS and advanced prostate cancer
2  Studies on MetS and biochemical recurrence 
3  Cohort studies on MetS and prostate cancer-specific mortality
547 Potentially relevant articles identified from MEDLINE EMBASE
195 Potentially relevant articles evaluated
352 Excluded
219 Review
21   Animal studies 
87   Abstract only
33   Editorial
9     Meta-analysis
23 Evaluated in detail (full text)
172 Excluded
Did not study MetS as exposure and prostate 
cancer risk or parameters of prostate   cancer  
as outcome
6 Excluded
1 Study on MetS factors and prostate cancer     
risk without a standard MetS definition. 
2 Published previously on the same or  subset of  
the  database
1 Study on MetS aand prostate cancer risk of  
re-biopsy
1 Study on MetS factors and biochemical   
recurrence without a standard MetS definition 
1 Case-control study on MetS and prostate   
cancer risk
2 Additional retrieved from bibliography  
Figure 1 Selection of studies for meta-analysis.
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tests (Egger P = 0.27 and 0.64 for prostate cancer risk and
Gleason score respectively).
Discussion
In 2007, Hsing et al. summarized five studies on MetS and
prostate cancer risk and concluded that the epidemiologic
evidence was insufficient to suggest a link between MetSNOTE: Weights are from random effects analysis














Figure 2 RR of prostate cancer risk for MetS presence.and PCa [37]. In 2012, Esposito et al. performed a
systematical review and meta-analysis on the association
of MetS and cancer risk including prostate cancer. The
authors also concluded that MetS was not associated with
prostate cancer risk too [22]. In the present study, we
updated the data and used the current evidence to analyze
whether MetS is associated with prostate cancer risk. We

























NOTE: Weights are from random effects analysis






























Risk of high grade Gleason prostate cancer
Figure 3 RR of high grade Gleason prostate cancer risk for MetS presence.
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cancer.
We believe the result is reliable for two reasons. Firstly,
only longitudinal cohort studies were included in this ana-
lysis, imparting strong evidence for our conclusions. In
addition, the association between MetS and prostate cancer
may be affected by several factors, including heterogeneity
among the individual studies. The heterogeneity may arise
from differences in age, race, the definition of MetS [22],








Risk of advanced p
Figure 4 RR of advanced clinical stage for MetS presence.composed of at least 3 components, and the individual
component may exert antagonistic functions on one
another Thus the syndrome may represent an integrated
outcome that combines neutralizing positive and negative
functions. For example, a meta-analysis revealed that
diabetes mellitus was significantly negatively associated
with prostate cancer risk in population-based studies
(RR = 0.72, 95% CI: 0.64-0.81) and cohort studies
conducted in the USA (RR = 0.79, 95% CI: 0.73, 0.86)















NOTE: Weights are from random effects analysis















Risk of biochemical recurrence
Figure 5 RR of biochemical recurrence for MetS presence.
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cancer share certain genetic factors, including the
HNF1β and JAZF1 genes, and a previous study sug-
gested that JAZF1 might represent a potential target
against diabetes and obesity [39]. Although hyperten-
sion was found to be positively associated with pros-
tate cancer risk [33,40-42], Obesity is negatively with
localized prostate cancer (0.94, 95% CI, 0.91-0.97)
and positively associated with advanced prostate can-







Risk of prostate canc
Figure 6 RR of prostate cancer-specific mortality for MetS presence.However, after analyses of several parameters of PCa
aggressiveness and progression, we found MetS to be
significantly associated with an increased risk of prostate
cancer with a high-Gleason score or advanced clinical
stage, with biochemical recurrence after primary trea-
tment and with prostate cancer-specific mortality. If
confirmed by more investigations, this finding may open
a new research field on PCa development and progres-
sion, potentially leading to new strategies or methods for


































High grade Gleason score
Prostate cancer risk
Figure 7 Funnel plot with pseudo 95% confidence limits.
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tumor, accounts for 29% of all cancer cases and the
second most common cause of death by cancer among
men in the USA [44]. Therefore we believe that there is
a compelling need to investigate this association between
MetS and prostate cancer although the association is
not strong.
Nevertheless, the reliability of these results is limited.
First, Gleason score and clinical stage data were
extracted from cross-sectional studies not longitudinal
cohort studies. Second, there exists a small difference
among studies on the definition of high-grade Gleason
PCa, some authors defined a high Gleason score ≥ 7
whereas others defined a high score as >7. Third, the
pathological stage data in some studies were from biopsy
not radical prostatectomy specimens. Last but not
least, to date there remains limited studies focusingon this association, although many of the available
studies are well designed case-control or longitudinal
cohort studies.
In addition to the limitations listed above, another
limitation for the analyses of the association between
MetS and prostate cancer risk or prostate cancer
parameters is that we did not perform a meta-regression
to attempt to explain the heterogeneity of the study
because of the varying adjustments in the individual
studies. The result of a recent meta-analysis on 9 cross-
sectional studies of metabolic syndrome in adult cancer
survivors increases the weight of this suspicion, as it
revealed that no significant association was found for non-
hematologic malignancies, including testicular tumor,
prostate cancer, sarcoma, and epithelial ovarian [45].
Therefore, there is an urgent future need to confirm this
association and to find potential mechanisms to explain
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sion of PCa.
Conclusions
Based on the current findings, MetS is not associated
with prostate cancer risk, but preliminary evidences
demonstrates that men with MetS more frequently
suffer high-grade prostate cancer, more advanced disease
and are at greater risk of progression after radical pros-
tatectomy and prostate cancer-specific death. Together,
these findings indicate that MetS may be associated with
the progression of prostate cancer and adverse clinical
outcomes. Further studies with adjustment for appro-
priate confounders and larger, prospective, multicenter
investigations are required in the future.
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